|
|
Influenza remains a devastating disease.
Current seasonal vaccines triggering an antibody response against surface antigens (hemagglutinin and neuraminidase) are only partially effective, especially for patients over 65 years old : 25% effectiveness in the 2016-17 season in the US (3)
A paradigm shift is essential in influenza vaccination
Osivax is developing a game-changing universal influenza vaccine
- Osivax’s vaccine targets the NucleoProtein (NP), a highly conserved internal antigen, much less prone to mutations than the traditional surface antigens targeted by current flu vaccines, thus alleviating the need for annual updates
- oligoDOM® technology enables the transformation of the NucleoProtein into a highly immunogenic antigen to trigger powerful B- and T-cells immune responses
Preclinical development on OVX836 universal flu vaccine candidate showed:
OVX836 is a Phase IIa clinical trial, conducted by Dr Isabel Leroux-Roels in The Center for Vaccinology of the Ghent University (CEVAC).
- powerful systemic and local immune responses
- strong efficacy in mice and ferrets challenge studies with multiple Flu viruses
- an excellent safety profile in a GLP preclinical toxicology study
OVX836 is a Phase IIa clinical trial, conducted by Dr Isabel Leroux-Roels in The Center for Vaccinology of the Ghent University (CEVAC).
1 - https://www.cdc.gov/flu/about/disease/us_flu-related_deaths.htm
2 - Institute for Disease Modelling, mentionned by Bill and Melinda Gates Foundation
3 - https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2017-06/flu-03-ferdinands.pdf
2 - Institute for Disease Modelling, mentionned by Bill and Melinda Gates Foundation
3 - https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2017-06/flu-03-ferdinands.pdf
|
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 961112
|
|